Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous antigen-activated dendritic cell immunotherapy (Research Institute of Fundamental and Clinical Immunology)
- Development stage
- Unknown
- Lead developer
- Research Institute of Fundamental and Clinical Immunology
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intravenous
01
Overview
This investigational autologous dendritic cell-based immunotherapy is being developed by the Research Institute of Fundamental and Clinical Immunology in Novosibirsk, Russia, for the treatment of colorectal cancer. The therapy utilizes dendritic cells (DCs) derived from a patient's own peripheral blood monocytes. These cells are transfected with DNA constructs encoding epitopes of specific tumor-associated antigens (TAAs), including carcinoembryonic antigen (CEA), epithelial cell adhesion molecule (EpCAM), and mucin 4 (MUC4). Once activated and loaded with these antigens, the dendritic cells are re-infused into the patient to stimulate a targeted antitumor cytotoxic T lymphocyte (CTL) response. The treatment is currently being evaluated in early-phase clinical trials for patients with stage II-IV colorectal cancer to assess safety and laboratory efficacy in preventing recurrence and treating secondary foci.
- Other names
- Immunotherapy based on dendritic cellsAutogemotherapy based on autologous antigen-activated dendritic cellsAutologous dendritic cell immunotherapy
Beyond the preview
Go deeper on Autologous antigen-activated dendritic cell immunotherapy (Research Institute of Fundamental and Clinical Immunology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autologous antigen-activated dendritic cell immunotherapy (Research Institute of Fundamental and Clinical Immunology).